July 11, 2025

Delayed Breast Cancer Care Triples Death Risk

Delays longer than 90 days before seeking care for breast cancer were linked to a threefold increase in two-year mortality, particularly affecting older and socially isolated patients, according to a multicenter Spanish study.

Conexiant

July 10, 2025

HHS Scraps Preventive Care Panel Meeting

HHS unexpectedly canceled a meeting of the U.S. Preventive Services Task Force, prompting fears it may be dismantled following similar moves by Secretary Robert F. Kennedy Jr. at other federal health agencies.

Conexiant

July 09, 2025

Recombinant Zoster Vaccine Linked to New-Onset Lupus

Researchers report the first documented case of systemic lupus erythematosus following Shingrix vaccination.

Conexiant

July 09, 2025

Chemotherapy Leaves Long-Lasting DNA Scars in Blood

Chemotherapy, while targeting cancer cells, also leaves a lasting mark on normal blood cells by introducing DNA mutations that can persist for decades.

Conexiant

July 09, 2025

E. coli Upcycle Turns Plastic to Pills

Scientists engineered E. coli to perform a synthetic chemical reaction that enables the conversion of plastic waste into the common drug paracetamol using a non-toxic, phosphate-driven process inside living cells.

Conexiant

July 03, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

July 02, 2025

FDA Approves Ready-to-Infuse Vancomycin

Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.

Conexiant

June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Retifanlimab-dlwr Approved for Anal Cancer in Combination With Carboplatin Plus Paclitaxel and as a Single Agent

The U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inopera...

The ASCO Post